Your signal. Your price.
U.S. regulators approved a breakthrough drug that doubles the survival rate of pancreatic cancer patients compared to standard chemotherapy. The daily two-pill treatment represents a historic advancement for a historically terminal disease.
Steve Young became the first patient to receive Moderna's personalized mRNA cancer vaccine in a clinical trial. The therapy combines customized mRNA with standard immunotherapy to drastically lower melanoma recurrence rates.
Natasha Loader notes that cancer vaccines historically failed because tumors suppress the immune system and evolve past single-protein targets. Modern trials utilize checkpoint inhibitors developed over the last 15 years to bypass this suppression.
Natasha Loader warns that personalized mRNA cancer therapies face steep hurdles regarding production costs, overall survival data, and patient tolerance. High manufacturing costs may prevent these highly tailored treatments from becoming widely accessible.
Calorie restriction and fasting-mimicking diets stimulate mitophagy, a selective recycling process that purges old, dysfunctional cellular components. Palmer references research by David Sinclair identifying mitochondrial decay as the primary driver of biological aging.
Brett Winton reports Moderna's Phase 3 cancer vaccine trial yielded positive results for aggressive melanoma. The customized mRNA treatment acts therapeutically post-surgery, training the immune system to target patient-specific neoantigens.
Combining Moderna's vaccine with Merck's Keytruda reduces advanced melanoma mortality by approximately 50 percent compared to Keytruda alone. Brett Winton notes the customized therapies currently cost $200,000 to $300,000 per patient, restricting early-stage use.
Lon Harris describes using the Ro.co platform to acquire a Wegovy pill prescription, losing nine pounds on a starter dose. Harris will transition from a 1.5 milligram dose to higher strengths to maximize weight loss.
Daisy Fancourt notes that regular arts engagement keeps amateur and professional brains five to seven years younger than chronological ages. This builds cognitive reserve, delaying outward dementia symptoms even if Alzheimer's plaques accumulate in the brain.
Masud Husain highlights data showing that maintaining social relationships, remaining curious, and pursuing a strong sense of purpose significantly lower the risk of developing dementia. These cognitive and social habits build neurological resilience to cognitive decline over time.
Masud Husain cites the Harvard study of aging, which tracked men from their late teens to their older years. The study revealed that average individuals who did not achieve soaring ambition self-reported the highest levels of overall happiness in life.
Dr. David Sinclair states his lab has initiated human clinical trials for ER-100, an epigenetic reversal gene therapy targeting blindness. The treatment uses a subset of Yamanaka factors delivered locally to the eye to safely reverse tissue age.
Dr. David Sinclair explains that delivering three Yamanaka genes, excluding the oncogenic C-Myc gene, resets cellular age by roughly 75 percent. This process restores the epigenome, which acts as cellular software directing how DNA is compacted.
Dr. David Sinclair reveals his lab developed an oral chemical cocktail that rejuvenated memory and skin quality in old mice within a month. The cocktail works epigenetically through TET enzymes, which strip regulatory chemicals off the DNA.
Dr. David Sinclair advocates for extended fasting, stating he regularly undergoes two-week fasts drinking only zero-calorie liquids and targeted supplements. He notes that chaperone-mediated autophagy, which cleanses misfolded proteins, kicks in after three days.
Dr. David Sinclair cites research by Rafael de Cabo showing that mice restricted to a narrow feeding window lived significantly longer than mice eating the same calories continuously. The timing of food intake outweighs the macronutrient composition.
Dr. David Sinclair warns that constant meat consumption continuously activates mTOR, which shortens animal lifespans. He recommends relying primarily on plant proteins, which are lower in branched-chain amino acids, and pulsing protein intake to build muscle.
Dr. David Sinclair takes daily low-dose Tadalafil to prevent the age-related decline of microvascular blood flow. He argues that maintaining vascular perfusion protects the brain from dementia, prevents prostate issues, and preserves hair follicles.
Dr. David Sinclair warns that commercial NMN supplements often contain bacterial endotoxins from manufacturing or lack NMN entirely. He cites research by Andrea Meyer finding significant purity issues in retail NMN products.
Dr. David Sinclair praises Brian Johnson for popularizing longevity science. He notes that Brian Johnson's public blood work shows a DunedinPACE aging rate of roughly 0.4, which is among the lowest recorded for a human.
Dr. David Sinclair notes that human data supporting sauna use for reducing cardiovascular disease is ten to twenty times stronger than the data for cold plunges. However, cold exposure successfully builds metabolic brown fat reserves.
Dr. David Sinclair is launching Lifespan.com, a community and magazine centered on peer-reviewed longevity research. The initiative aims to democratize access to pure supplement testing and advanced aging metrics like Steve Horvath's epigenetic clock.
Chris Williamson shares that his cholesterol spiked to the 400s during a carnivore diet, prompting him to get a Clearly contrast scan. The non-invasive scan detected mild plaque progression, leading him to transition to a low-fat Mediterranean diet.
Dr. David Sinclair highlights a two-decade rhesus macaque study led by Rosalind Anderson, which proved that calorie-restricted monkeys lived longer. The restricted monkeys also experienced a significantly lower burden of cancer and cardiovascular disease.
Peter Attia argues that liver disease is not an isolated organ issue but a parallel expression of systemic metabolic dysfunction. This dysfunction is widespread, with fatty liver disease estimated to affect more than 38% of the world's adult population.
Peter Attia outlines four progressive stages of metabolic liver disease: metabolic stress, steatosis, steatohepatitis, and fibrosis. The first three stages remain largely reversible, but advanced fibrosis causes structural damage that is permanent and increases cardiovascular and cancer risks.
Peter Attia notes that visceral fat drains directly into the portal vein, delivering a concentrated stream of fatty acids to the liver. This anatomical pathway makes visceral fat a highly potent driver of liver steatosis and metabolic mortality.
Patients with over 200 square centimeters of visceral fat have a 7.5-fold higher risk of liver steatosis than those below 100 square centimeters. NHANES data shows MASLD patients in the highest visceral fat quartile face a 3.5-fold higher mortality rate.
Peter Attia emphasizes resistance training because skeletal muscle stores roughly 75% of the body's glycogen, compared to 25% in the liver. Gaining muscle significantly improves recovery, as demonstrated by a Korean study where muscle gain quadrupled MASLD resolution rates.
Combining metabolic dysfunction with alcohol consumption dramatically worsens health outcomes. NHANES data shows that patients with cardiometabolic risk and steatosis who consume moderate alcohol have a 15-fold increase in liver-specific mortality and a 2.35-fold increase in cancer mortality.